Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Cash from Operations (2022 - 2025)

Taysha Gene Therapies' Cash from Operations history spans 4 years, with the latest figure at 24166000.0 for Q3 2025.

  • For Q3 2025, Cash from Operations fell 11.8% year-over-year to 24166000.0; the TTM value through Sep 2025 reached 84676000.0, down 7.14%, while the annual FY2024 figure was 81225000.0, 11.24% down from the prior year.
  • Cash from Operations for Q3 2025 was 24166000.0 at Taysha Gene Therapies, down from 20182000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 14712000.0 in Q4 2022 and bottomed at 40939000.0 in Q1 2022.
  • The 4-year median for Cash from Operations is 20185000.0 (2023), against an average of 20600066.67.
  • The largest YoY upside for Cash from Operations was 50.69% in 2023 against a maximum downside of 209.55% in 2023.
  • A 4-year view of Cash from Operations shows it stood at 14712000.0 in 2022, then tumbled by 209.55% to 16117000.0 in 2023, then decreased by 13.59% to 18308000.0 in 2024, then crashed by 32.0% to 24166000.0 in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Cash from Operations are 24166000.0 (Q3 2025), 20182000.0 (Q2 2025), and 22020000.0 (Q1 2025).